Blog Posts - Genotype 4



Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5

-- High Cure Rates Observed Across a Range of Genotypes -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 25, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two studies evaluating the safety and efficacy of investigational uses of...
by Hepatitis C Research and News on Apr 25, 2015

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C

- The New Drug Application (NDA) was accepted by the U.S. Food and Drug Administration (FDA) and is based on results from the PEARL-I study, which demonstrated up to 100 percent sustained virologic response rates at 12 weeks post-treatment with no di...
by Hepatitis C Research and News on Apr 24, 2015

Enanta Announces U.S. FDA Grants Priority Review for AbbVie’s Investigational, All-Oral, Interferon-Free Treatment Regimen for Genotype 4 Chronic Hepatitis C Infection

April 23, 2015 08:16 AM Eastern Daylight Time WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and...
by Hepatitis C Research and News on Apr 23, 2015

Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease

-- High Cure Rates in More Than 600 Genotype 1 and 4 Patients With Limited or No Approved Treatment Options -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 23, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 clinic...
by Hepatitis C Research and News on Apr 23, 2015

Interferon-free Regimen Effective for Genotype-4 Chronic Hepatitis C

By Will Boggs MD April 13, 2015 NEW YORK (Reuters Health) - An all-oral, interferon-free regimen consisting of ombitasvir, paritaprevir and ritonavir is effective at treating patients with genotype-4 chronic hepatitis C virus (HCV), according to a...
by Hepatitis C Research and News on Apr 14, 2015

AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at the Liver Meeting 2014

- Results demonstrated high response rates in adult chronic hepatitis C genotype 4 patients without cirrhosis - Data underscore AbbVie's commitment to evaluating treatments across a range of patients with chronic hepatitis C virus infection Nov 11,...
by Hepatitis C Research and News on Nov 11, 2014

OLYSIO™ available soon in all Nordic countries for the treatment of adults with hepatitis C genotype 1 and 4 infection

10-Jun-14 06:30 Treatment of hepatitis C patients with Olysio (simeprevir) has begun in Sweden, Finland and Denmark Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that Olysio will be available in all of the Nordic countries withi...
by Hepatitis C Research and News on Jun 15, 2014

My Treatment Approach to Chronic Hepatitis C Virus (Genotypes 1–6)

Article in Press Mitchell L. Shiffman, MD, April G. Long, NP, Amy James, FNP, Phillip Alexander, NP Published Online: May 24, 2014 DOI: http://dx.doi.org/10.1016/j.mayocp.2014.04.013 Publication stage: In Press Corrected Proof...
by Hepatitis C Research and News on Jun 14, 2014

Simeprevir approved in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

OLYSIO™ (Simeprevir) provides a new triple therapy treatment option, as well as the first ever 12-week interferon-free and ribavirin independent treatment regimen, in combination with sofosbuvir, for appropriate patients in Europe Stockholm, Swed...
by Hepatitis C Research and News on May 16, 2014

Final data from the phase II COSMOS study with Simeprevir in combination with Sofosbuvir presented at EASL

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that positive new simeprevir data were presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) in London. The data presented i...
by Hepatitis C Research and News on Apr 12, 2014

Final Data from the Phase 2 COSMOS Study of Janssen’s Once-Daily Simeprevir in Combination with Sofosbuvir Presented at the International Liver Congress™

Additional Analyses Presented in European and Hepatitis C Genotype 4 Patient Subgroups Underscore Benefit of Simeprevir-based Treatment Regimens April 12, 2014 11:24 AM Eastern Daylight Time LONDON--(BUSINESS WIRE)--Janssen R&D Ireland (Janssen...
by Hepatitis C Research and News on Apr 12, 2014

New data for HCV genotype 4 patients with simeprevir- and sofosbuvir-based regimens

PUBLIC RELEASE DATE: 12-Apr-2014 Contact: Courtney Lock courtney.lock@cohnwolfe.com 44-789-438-6422 European Association for the Study of the Liver London, UK, Saturday 12 April 2014: Results from RESTORE , a phase III, multicentre, s...
by Hepatitis C Research and News on Apr 12, 2014

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4

Liver Int. 2014 Jan 19. doi: 10.1111/liv.12471. [Epub ahead of print] Everson G, Cooper C, Hézode C, Shiffman ML, Yoshida E, Beltran-Jaramillo T, Andreone P, Bruno S, Ferenci P, Zeuzem S, Brunda M, Le Pogam S,Nájera I, Zhou J, Navarro MT, Voulgari...
by Hepatitis C Research and News on Feb 15, 2014

Clinical Trial: A Phase III Evaluation of Daclatasvir + Sofosbuvir in Genotype 1-6 Chronic HCV Subjects With Cirrhosis Who May Require Future Liver Transplant and Subjects Post-Liver Transplant

This study is not yet open for participant recruitment. Verified January 2014 by Bristol-Myers Squibb Sponsor: Bristol-Myers Squibb Information provided by (Responsible Party): Bristol-Myers Squibb ClinicalTrials.gov Identifier: NCT02032875 F...
by Hepatitis C Research and News on Jan 11, 2014

Simeprevir has been approved in the USA as a new treatment for hepatitis C

<<<<<<<<...
by PennyOmega.com on Nov 24, 2013

Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6

Alimentary Pharmacology & Therapeutics Early View (Online Version of Record published before inclusion in an issue) Review Article You have free access to this content J. M. Wantuck1, A. Ahmed2, M. H. Nguyen2,* Article first published online...
by Hepatitis C Research and News on Nov 20, 2013

New GT-1b Data from ABT-450 Containing Regimen Being Presented at The Liver Meeting

SVR12 Rates of 95% in HCV Treatment Naïve Patients and 90% in Prior Null Responders Reported in PEARL-I Study WATERTOWN, Mass.--(BUSINESS WIRE)--Nov. 3, 2013-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechn...

FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection

- Final FDA Decision on Sofosbuvir Anticipated by December 8, 2013 - FOSTER CITY, Calif., Oct 25, 2013 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Admi...
by Hepatitis C Research and News on Oct 25, 2013

Briefing Information for the October 25, 2013 Meeting of the Antiviral Drugs Advisory Committee - Sofosbuvir

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance FDA Disclaimer: Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FO...
by Hepatitis C Research and News on Oct 23, 2013

FDA review heralds first-in-class status for Gilead's hep C drug sofosbuvir

Provided by FierceBiotech October 23, 2013 | By John Carroll Friday's FDA panel review of Gilead's hep C drug sofosbuvir is shaping up as a marketing event. In an internal staff review released this morning, regulators said that the hep C drug combin...
by Hepatitis C Research and News on Oct 23, 2013


Trending Topics

Close